ANALISIS EFEKTIVITAS DAN BIAYA PENGGUNAAN SITIKOLIN DAN PIRASETAM PADA PASIEN STROKE ISKEMIK DI BANGSAL RAWAT INAP RUMAH SAKIT

https://doi.org/10.22146/jmpf.201

Nur Santi(1*), Zullies Ikawati(2), Satibi Satibi(3)

(1) 
(2) 
(3) 
(*) Corresponding Author

Abstract


Salah satu terapi yang diberikan dalam penanganan pasien stroke iskemik adalah neuroprotektan yaitu sitikolin dan pirasetam dengan jumlah pemakaian yang sangat besar. Biaya obat - obatan tersebut paling besar diantara biaya obat lainnya dalam pengobatan stroke, sedangkan efektivitas kedua obat tersebut terhadap perbaikan kondisi neurologis pasien stroke iskemik masih kontroversial. Penelitian ini bertujuan untuk mengetahui perbandingan efektivitas antara sitikolin dan pirasetam terhadap perbaikan fungsi neurologis dan mengetahui perbandingan biaya penggunaan sitikolin dan pirasetam pada pasien stroke iskemik.  Penelitian ini menggunakan metode non-eksperimental dengan rancangan kohort perspektif. Data diambil secara prospektif terhadap pasien stroke iskemik di bangsal rawat inap RSUD  Undata Palu selama November 2012-Februari 2013 dengan total sampel 48 pasien yang memenuhi kriteria inklusi. Efektivitas  erapi sitikolin dan pirasetam terhadap perbaikan fungsi neurologis dinilai berdasarkan skor GCS (Glasgow Coma Scale) kemudian dilakukan analisis biaya perawatan dengan menghitung biaya medis langsung (direct medical cost). Hasil penelitian menunjukan bahwa pasien stroke iskemik yang mendapat terapi sitikolin dibandingkan pirasetam tidak menunjukan adanya perbaikan fungsi neurologis dengan nilai signifikasi 0,295 (p > 0,05). Rata-rata biaya obat, rata-rata biaya non obat, dan rata-rata biaya total perawatan pasien stroke iskemik kelompok sitikolin dibandingkan pirasetam berututan adalah Rp 423.123 dan Rp 616.548, Rp 2.200.208 dan Rp 2.580.287, Rp 2.623.331 dan Rp 3.196.835.

 

Kata kunci: efektivitas, biaya, biaya medis langsung, sitikolin, pirasetam


Full Text:

Untitled


References

Adams,  J.R.,  Harold,  P.,Gregory,D.Z.,Mark,  J.A.,Deepak,L.B.,Lawrence.B.,et   al. 2007, Gudlines for the Early Management of Adult with Ischemic Stroke, American Heart Association, 38: 1655-1711.

Adams,J.R.,  Larry,B.G.,  Mark,J.A.,  Lawrence,J.A.,  Lawrence,M.B., Cheryl,D.B.,et.al, 2006, Primary Prevention of Ischemic Stroke, American Heart Association, 37: 1583-1633.

Alan, S.G., Mozzafarian, D., Roger, L.V., Benjamin, E.J., Berry, D.J., Borden, W.B., et, al, 2013, Heart Deseases and Stroke Statistics, Circulation American Heart Association, 127 : e6-e245.

Bruhwyler, J., Dorpe, V. J., Geczy, J., 1997, Multicenter Open-Label Study of The Efficacy and Tolerability of Citicoline in The Treatment of Acute Cerebral Infraction, Current Therapeutic Research, 58 : 5.

Casado, A., Secades, J.J, Ibarz, R., Herdman, M., Brosa, M., 2008, Cost Effectiveness of Citicoline Versus Conventional Treatment in Acute Ischemic Stroke, Expert Reviews, 8 (2) : 151-157.

Davalos, A., Castillo, J., Sabin, J.A., Secadel, J.J., Mercadal, J., Lopez, S.,et al, 2002, Oral Citicolin in Acut Ischemic Stroke, American Heart Association, 33 : 2850-2857.

Dipiro, J.T., Talbret, L.R., Yee, G.C., Matzke, J.R., Wels, B.G., Posey, L.M., 2005, Pharmacotherapy   A  Pathophysiologic   Approach,  7  th  edition,  Mc  Graw  Hill Medical, New York.

Dostovic, Z., Smajlovic, D., Dostovic, E., Ibrahimagic, O. C., 2012, Stroke and Disorder  of  Consciousness,  Volume  2012,  Cardiovasculer  Pscychiatri  and Neurology, Hindawy Publishing, Bosnia Herzegovina.

Ginsberg, M. D., 2008, Neuroprotection  for Ischemic  Stroke  : Past, Present, and Future, Neuropharmacology Pubmed PMC, 55 (3) : 363-389.

Gofir, A., 2011, Manajemen Stroke, 2 th edition, Cendekia Press, Yogyakarta.

Gualtieri, F., Manetti, D., Romanelli, M. N., Ghelardini, C., 2002, Design and Study of Piracetam-like Nootropics, Controversial Members of The Problematic Class of Cognition- Enhancing Drugs, Curr Pharmaceutical Design, 8 : 125-138.

Hamidon, B., Raymond, A.A., 2003, Predictors of In- Hospital Mortality After an Acute Ischemic Stroke, Neuro Journal Southeas Asia, 8 : 5-8.

Hillen, T., Dundas, R., Lawrence, E., Stewart, A. J., Rudd, G. A., Charles, D. A., et. al, 2000, Antithrombotic And Antihypertensive Management 3 Month After Ischemic Stroke, American Hearth Association, 31: 469-475.

Ikawati, Z., 2011, Farmakoterapi Penyakit Sistem Syaraf Pusat, Bursa Ilmu, Yogyakarta.

Jennet, B., 2005, Development of Glasgow Coma and Outcome Scale, Nepal Journal of Neuroscience, 2 : 24-28.

Junaidi, I., Tandung, D.,(ed). 2011, Stroke Waspadai Ancamannya, Andi Offset, Yogyakarta.

Kessler, J., Karbe, H. T., Heiss, W. D., 2000, Piracetam Improves Activated Blood Flow and Facilities Rehabilitation of Poststroke Aphasic Patiens, American Heart Association, 31 : 2112-2116.

Kim,  Y.  J.,  Cho,  H.  J.,  2009,  Efficacy  and  Safety  of Oral  Citicholine  in  Acute Ischemic Stroke, Pubmed PMC, 3 : 171-176.

Kornbluth, J, Bhardwajh, A., 2010, Evaluation of Coma : A Critical Appraisal of Popular Scoring System, Neurocritical Care Society, Boston.

Leng, C., Lin, M. D., Yang, J.T., Weng, H.H., Hsiao, C.T., Lai, L.S., et. al, 2011, Predictors of Early Clinical Deterioration After Acute Ischemic Stroke, The American Journal of Emegency Medicine, 29 : 557-581.

Misbach, J., Tobing, L., Ranakusuma, T. A. S., Suryamiharja, A., Harris, S., Bustami, M., 2007, Guidelines Stroke 2007, Kelompok Studi Serebrovascular Perhimpunan Dokter Spesialis Saraf Indonesia (PERDOSSI), Hal : 85-87.

Nufus, H., 2012   Peran Citicolin untuk Tatalaksana Stroke Iskemik Akut, Majalah Fokus,       38       (1)       :       1       diakses       pada       12       September       2012,<www.webicina.com/personalized/recent/?source =2873&cat=0&page=1.

Orion,  1997,  Pharmacoeconomics  Primer  and  Guide  Introduction  to  Economic Evaluation, Hoesch Marrion Rousell, Virginia Qureshi, I., Endres, R.J., 2010, Citicoline : A Novel Therapeutic Agent With Neuroprotective Neuromodulatory, and Neuoregenerative  Propertise,  Natural Medicine Journal, 2 (6) : 1-11.

Reeder, C. E., 1995, Overview of Pharmacoeconomics and Pharmaceutical Outcomes Evaluation, American Journal of Health System Pharmacy.

Ricci, S., Celani, M. G., Cantissani, T. A., Righetti, E.,2012,   Piracetam For Acute Ischemic Stroke, The Chocrane Collaboration.

Rosjidi, C., dan  Nurhidayat,  S., 2008, Buku  Ajar  Perawatan  Cedera  Kepala dan Stroke, Ardana Media, Yogyakarta, Hal : 143-188.

Saka, O., McGuire, A., Wolfe, C., 2009, Cost of Stroke in The United Kingdom, Age and Ageing, 38 : 27-32.

Shiddique, N. A., Nur, Z., Mahbub, S., Alam, B., 2009, Clinical Presentation And Epidemiology of Stroke – A Study of 100 Cases, Journal Medicine, 10 : 86-89.

Small, L. S., Liano, D. A., 2009, Biological Approaches To Aphasia Treatment, Curr Neuronal Neurosci, 9 (6) : 443-450.

Sternbach,  G.  L,  2000,  The  Glasgow  Coma  Scale,  The  Journal  of  Emergency Medicine, 19 : 67-71.

Tjiptoherijanto, P. S.B., 1994, Ekonomi Kesehatan, Rineka Cipta, Jakarta.

Ustrell,   R.   X.,   2007,   Stroke,   Diagnosis   and   Therapeutic   Management   of Cerebrovascular Desease, Puesta Al Dia, Spain.

Vogenberg, F. (2001). Introduction To Applied Pharmacoeconomics. USA: McGraw- Hill Companies.

Wayne,  M.  C.,  Bejamin,  J.  W.,  Kenneth,  A.  S.,  Richard,  M. Z.,  LuAnn,  A.  S., Richard, E. G., 1999, A Randomized  Efficacy Trial of Citicholine in Patient with Acute Ischemic Stroke, American Heart Association, 30 : 2592- 2597.

Weir, C. J., Bradford, A. V. J., Lees, K. R., 2003, The Prognostic  Value of The Components of Glasgow Coma Scale Following Acute Stroke, Q J Med, 96 : 67-74.

Wolfe, C. D. (2000). The Impact of Stroke. British Medical Journal, departement of Public Health Sciences .

Zalfonte, R., Friedewald, W. T., Lee, S. M., Levin, B., Arrazia, R. D., Ansel, B., et. al, 2009, The Citicholin Brain Injury Treatment (CORBIT) Trial : Design and Methodes, Journal of Neurotrauma, 26 : 2207-2216.



DOI: https://doi.org/10.22146/jmpf.201

Article Metrics

Abstract views : 716 | views : 3439

Refbacks

  • There are currently no refbacks.


Copyright (c) 2013 JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice)

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

©Jurnal Manajemen dan Pelayanan Farmasi
Faculty of Pharmacy
Universitas Gadjah Mada
Creative Commons License
View My Stats